This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Breakout Stocks to Watch Going Into Labor Day

NEW YORK (TheStreet) -- A lot of stocks we follow closely are doing very well, and here are four to watch for continued upside.

Arista Networks (ANET - Get Report) did very well on Wednesday. It exploded from just under $76, ran up to $83.47, and closed at $83.15, up $6.99, or 9.2%, on 724,200 shares traded. That's a lot of volume for that stock, and the best volume in about two-and-a-half weeks. With the breakout across lateral resistance at recent highs, this stock could head up towards $92-$93 in the short term. At around $82.50, shares are up nearly 50% for the year to date.

BioDelivery Sciences International (BDSI - Get Report) , one of our swing trade picks, is also acting well. It popped 5% on Wednesday, up 82 cents to $15.48, breaking through lateral resistance and the double-top that's been holding it back since July. The target is $19 and then $21. At close to $16, the stock is up 169% for the year to date.

Keryx Biopharmaceuticals (KERX - Get Report) appears to be breaking out. Intermediate resistance in the $18 range was taken out on Wednesday, as the stock gained 95 cents, or 5.5%, to $18.18. Watch for a move next to the $20 range short-term, and then secondary target at $22-$22.50. Shares are currently around $18, up 39% for the year to date.

Sunesis Pharmaceuticals (SNSS - Get Report) popped on Wednesday, up 74 cents, or about 10%, to $8.23 on 5.2 million shares. That's the biggest volume since the beginning of the year, and comes on a breakout day when it moved across resistance going back to late 2012. At this point, look for SNSS to run to $12 and then potentially to $15. Shares, at close to $8, are up nearly 65% year to date.

See Harry's video chart analysis on these stocks.

At the time of publication, the author held no positions in any of the stocks mentioned, although positions may change at any time.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

TheStreet Ratings team rates KERYX BIOPHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate KERYX BIOPHARMACEUTICALS INC (KERX) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins."

You can view the full analysis from the report here: KERX Ratings Report

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANET $66.62 0.00%
BDSI $3.38 0.00%
KERX $5.44 0.00%
SNSS $0.51 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs